On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to address unmet and differentiated clinical needs in the global market. The company consistently adheres to an open cooperation strategy, actively exploring business development opportunities for its innovative drug pipeline with global peers while strengthening its internal R&D capabilities. Should any definitive cooperation agreements be reached in the future, the company will strictly comply with information disclosure regulations to fulfill its disclosure obligations.